French drugmaker Sanofi said on Friday it was looking into the separate listing of its Consumer Healthcare business from the fourth quarter of next year and that it plans to boost drug development ...

French drugmaker Sanofi said on Friday it was seeing an "unprecedented level" of demand for its antibody therapy to prevent respiratory syncytial virus (RSV), a leading cause of hospitalizations in...

Sanofi (SNY) and Teva enter into a collaboration deal to co-develop and co-commercialize the latter's inflammatory bowel disease candidate, TEV'574.

Teva Pharmaceutical Industries Ltd.'s TEVA, -4.10% new collaboration with Sanofi SNY, on an inflammatory bowel disease treatment “will pay dividends” from a commercial perspective, Evercore ISI ana...

Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop its treatment for ulcerative colitis and Crohn's disease that it expects to ultimatel...

Sanofi revealed Tuesday that it had entered into an agreement with Janssen for the joint development and marketing of a vaccine candidate targeting extra-intestinal pathogenic E.coli.

If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in ...

The French Pharma company is moving on an immunology franchise. Dupixent is the internal cash cow to drive lower debt and internal progress in the early-stage pipeline. Attractive valuation with a ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.